Compare Enveric Biosciences Inc (ENVB) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Phillips 66 — how do they compare? Enveric Biosciences Inc trades at $1.43 (market cap $5.32M), while Phillips 66 trades at $200.59 (market cap $78.65B). The key difference: Phillips 66 is far larger — about 14783.8× Enveric Biosciences Inc's market cap, and Phillips 66 pays a 2.59% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | PSX | |
|---|---|---|
Market Cap | $5.32M | $78.65B |
Sector | Health | Energy |
52-Week High | $17.40 | $201.45 |
52-Week Low | $1.28 | $118.37 |
Enterprise Value | $408.82K | $100.62B |
Dividend Yield | — | 2.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Phillips 66 (PSX) trades at $201.86, up 0.2% on the day, with a bullish technical signal and strong analyst support. The stock shows robust earnings beats in recent quarters, including Q1 2026's surprise profit, while maintaining solid profitability metrics like a 14.75% ROE. Recent news highlights refining margin strength and dividend consistency, with two $1.27 payouts in 2026. Cash flow trends improved in 2025, though revenue has declined from 2022 peaks.
PSX offers value with a P/E of 19.38 and P/S of 0.59, supported by 57% analyst buy ratings and a $201.50 consensus target. Risks include volatile refining margins, debt levels at 27.18% of assets, and revenue contraction since 2022. The stock's proximity to its 52-week high suggests limited near-term upside without new catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
